Manager Kim Heung-tae Emphasizes Investment in Bio, Semiconductors, and Nuclear Power

The purchase price was suggested to be below 18,800 won, and a staggered buying strategy was used.

The target price was set at 21,000 won, and its achievement was cited as an example of securing profit.

Manager Kim Heung-tae explained that the investment approach for the bio sector is changing. He diagnosed that former leading stocks like Alteogen and R&L Bio are currently undergoing a correction period.

He emphasized the need to diversify investment portfolios into bio companies that show actual performance and those that are undervalued. He added that a new approach is necessary, focusing on stocks with limited individual investor holdings.

He explained that a quantum leap for the company is expected once the merger is complete.

He evaluated AriBio Holdings as having very high future growth potential, with an expected profit of 7 trillion won from its technology export business. He advised that this merger issue and technological competitiveness could present investment opportunities.

The conversion price for these convertible bonds was set at 5,106 won.

Considering CP System's current market capitalization of approximately 140 billion won, a 10 billion won convertible bond issuance is a significant amount, he evaluated. Such an issuance can be a crucial factor affecting the company's fundraising and future stock price volatility.

The issued convertible bonds grant investors the right to convert them into shares, thus potentially acting as an overhang issue depending on future stock price movements. Therefore, it is necessary to thoroughly analyze the announcement details and observe market reactions.

While convertible bond issuance is a common means for companies to raise growth capital, the issuance size and conversion price can significantly impact existing shareholders, requiring continuous attention.